OR WAIT null SECS
July 15, 2025
Article
New phase 3 trial data reveals Dapirolizumab pegol significantly reduces disease activity and fatigue in systemic lupus erythematosus patients, promising improved treatment outcomes.
July 02, 2025
This FDA News Month in Review provides a round-up of regulatory decisions from June 2025.
June 27, 2025
We spotlight 7 impactful regulatory decisions scheduled to occur during the second half of 2025.
June 24, 2025
With the approval, children ≥ 5 years of age with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration.
June 10, 2025
Recent studies reveal belimumab's effectiveness in treating lupus nephritis, showing significant renal response and improved patient outcomes in real-world settings.
June 09, 2025
Video
Sayna Norouzi, MD, reflects on the recent progress in the therapeutic pipeline for lupus nephritis.
June 08, 2025
Sayna Norouzi, MD, discusses results from a pair of trials examining QoL in patients with lupus from ERA 2025.
June 05, 2025
New analysis reveals obinutuzumab's potential to improve kidney inflammation and biomarkers in lupus nephritis.
May 22, 2025
EMD Serono previously announced that its CLE cohort had met its primary endpoint while its SLE cohort failed to follow suit.
May 20, 2025
A recent meta-analysis confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus, potentially informing clinical management strategies.
